Skip to content
Clinical Trials – home

LEUPRORELIN: A Comprehensive Guide for Patients

6 / 10
trials open to patients / all trials
16+
Countries

In short

Leuprorelin, also known as leuprolide, is a hormone therapy drug used to treat various conditions. This article examines recent clinical trials investigating leuprorelin's use and effectiveness for conditions like prostate cancer, breast cancer, uterine fibroids, and other hormone-sensitive disorders. We'll explore the drug's mechanisms, administration methods, and potential benefits and side effects as revealed through these studies.

At a glance

Main Uses
Prostate cancer, breast cancer, uterine fibroids, central precocious puberty, SBMA
Administration
Subcutaneous injection, various depot formulations (1-month, 3-month)
Mechanism
GnRH agonist, suppresses LH and FSH production
Common Side Effects
Menopausal-like symptoms, injection site reactions, hormone level changes
Treatment Duration
Varies by condition, ranging from 12 weeks to several years
Efficacy Measures
Hormone suppression, tumor response, quality of life improvements
Safety Monitoring
Adverse events, serious adverse reactions, long-term effects

What is Leuprorelin?

Leuprorelin, also known as leuprolide acetate, is a synthetic hormone medication used to treat various conditions related to hormone imbalances. It belongs to a class of drugs called gonadotropin-releasing hormone (GnRH) agonists. Leuprorelin is available under several brand names, including Leuplin, Enantone, Trenantone, and TAP-144SR.

How Does Leuprorelin Work?

Leuprorelin works by mimicking the action of the natural GnRH hormone in the body. Initially, it stimulates the production of certain hormones, but with continuous use, it actually suppresses the production of sex hormones like testosterone and estrogen. This suppression is reversible, meaning hormone levels return to normal after stopping the medication.

Conditions Treated with Leuprorelin

Leuprorelin is used to treat several conditions, including:

  • Prostate Cancer: It helps suppress testosterone production, which can slow the growth of prostate cancer cells.
  • Breast Cancer: In premenopausal women with hormone-sensitive breast cancer, leuprorelin can be used as part of adjuvant therapy (additional treatment after primary treatment) to suppress estrogen production.
  • Uterine Fibroids: Leuprorelin can help reduce the size of uterine fibroids and alleviate associated symptoms.
  • Central Precocious Puberty: This is a condition where puberty starts too early in children. Leuprorelin can help pause puberty progression.
  • Endometriosis: By suppressing estrogen production, leuprorelin can help manage symptoms of endometriosis.
  • Spinal and Bulbar Muscular Atrophy (SBMA): This is a rare genetic disorder affecting motor neurons. Leuprorelin is being studied for its potential benefits in SBMA.

How is Leuprorelin Administered?

Leuprorelin is typically administered as a subcutaneous (under the skin) injection. It comes in different formulations:

  • Monthly depot: 3.75 mg injected once every 4 weeks.
  • 3-month depot: 11.25 mg injected once every 12 weeks.

The specific dosage and frequency may vary depending on the condition being treated and the individual patient's needs. Always follow your healthcare provider's instructions for administration.

Effectiveness of Leuprorelin

The effectiveness of leuprorelin can be measured in different ways depending on the condition being treated:

  • For prostate cancer, effectiveness is often measured by the rate of castration (suppression of testosterone) and progression-free survival.
  • In breast cancer treatment, researchers look at factors like progression-free survival and overall survival.
  • For central precocious puberty, effectiveness is measured by the suppression of hormones like luteinizing hormone (LH) and follicle-stimulating hormone (FSH).

Potential Side Effects

Like all medications, leuprorelin can cause side effects. Some common side effects may include:

  • Hot flashes or sweating
  • Changes in menstrual periods in women
  • Decreased sexual desire or ability
  • Fatigue
  • Headache
  • Mood changes
  • Injection site reactions (pain, redness, or swelling)

It's important to discuss any side effects you experience with your healthcare provider. They can help determine if the benefits of the treatment outweigh the risks for your specific situation.

Impact on Quality of Life

While leuprorelin can be effective in treating various conditions, it's also important to consider its impact on quality of life. Some studies have looked at how switching from monthly to 3-monthly injections affects patients:

  • Reduced frequency of medical visits
  • Potential relief from physical and emotional burden due to less frequent injections
  • Possible financial relief due to less frequent treatments
  • Changes in side effects or injection site pain

Your healthcare provider can help you weigh the benefits and potential impacts of leuprorelin treatment on your overall quality of life.

Questions people often ask

Conditions where Leuprorelin is being studied

Each condition opens its own overview and trial list

Trials with Leuprorelin

Recruiting trials first

See all 10 →
Quick filters
  • Participants:Adults
  • Participants:Adults
  • Participants:Adults
  • Participants:Adults
  • Participants:Adults
  • Participants:Adults
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.

Legal notice · Published by CTIN POLAND sp. z o.o., ul. rtm. Witolda Pileckiego 67/109, 02-781 Warsaw, Poland · KRS 0001111334 · REGON 528919042 · NIP 9512598637

© 2026 Clinical Trials EU – European Clinical Trials Information Network

GDPR compliance, ISO 9001 and ISO 27001 certified (LL-C Certification)

On this site, “treatment” means an investigational medicine being studied in a clinical trial. Its safety and efficacy for the use being studied have not yet been confirmed, some participants may receive a placebo or a comparator medicine, and taking part does not guarantee any health benefit. The decision to take part is made by the doctor at the research site. This site is for information only and does not replace medical advice.

This service is not affiliated with the European Commission, the EMA, or the official CTIS system. Most information comes from publicly available international clinical-trial registries, supplemented by data from academic sites, national regulators and commercial sponsors. On this site, “treatment” and “therapy” mean a medicine being tested in a clinical trial. Its safety and effectiveness in the use being studied are not yet confirmed, some participants may receive a placebo or a comparator, and taking part does not guarantee a health benefit. The doctor at the research site decides who can take part. This site provides information, not medical advice. Certain content and visual elements on this website have been generated or enhanced using artificial intelligence (AI).